Every peptide, lab-verified.

Investigational triple-agonist peptide (GLP-1/GIP/glucagon) developed by Eli Lilly, researched for metabolic regulation, weight management, and glucose control.

Dual GIP/GLP-1 receptor agonist developed by Eli Lilly, approved for type 2 diabetes (Mounjaro®) and chronic weight management (Zepbound®).

Synthetic 15-amino acid peptide derived from a gastric protein, researched for tissue repair, gut healing, tendon recovery, and anti-inflammatory effects.

Copper-binding tripeptide researched for skin regeneration, wound healing, collagen stimulation, and anti-aging effects.

Mitochondrial-derived peptide researched for metabolic regulation, exercise mimicry, insulin sensitivity, and longevity.

Synthetic growth hormone-releasing hormone (GHRH) analog, FDA-approved as Egrifta® for HIV-associated lipodystrophy. Researched for visceral fat reduction.

GLP-1 receptor agonist for blood sugar regulation and weight management. Sold as Ozempic®, Wegovy®, and Rybelsus®.

Selective growth hormone secretagogue (GHS) that stimulates pulsatile GH release with minimal effects on cortisol and prolactin.

Synthetic fragment of Thymosin Beta-4 researched for tissue repair, inflammation reduction, wound healing, and cardiac tissue recovery.

Nicotinamide adenine dinucleotide, a coenzyme essential for cellular energy metabolism, DNA repair, and sirtuin activation. Researched for aging and metabolic health.

Synthetic heptapeptide derived from tuftsin, researched for anxiolytic effects, immune modulation, and cognitive enhancement without sedation.

Synthetic heptapeptide derived from ACTH(4-10), researched for neuroprotection, cognitive enhancement, and brain injury recovery. Approved in Russia as a nootropic.

Modified growth hormone-releasing hormone (GHRH) analog for pulsatile GH release. Also known as Mod GRF (1-29). Shorter half-life than the DAC version.

Long-acting amylin receptor agonist developed by Novo Nordisk, researched for appetite regulation and weight management alongside semaglutide (CagriSema).

Synthetic alpha-MSH analog researched for skin pigmentation (tanning), photoprotection, and sexual function enhancement.

Anti-inflammatory tripeptide from α-MSH researched for gut health, skin barrier repair, and NF-κB inhibition.

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) researched for telomerase activation, telomere elongation, and potential anti-aging effects.

Melanocortin receptor agonist (bremelanotide) FDA-approved as Vyleesi® for hypoactive sexual desire disorder in premenopausal women.

Nine-amino acid neuropeptide researched for sleep regulation, stress adaptation, and normalization of disturbed sleep architecture.

Thymic peptide researched for immune modulation, T-cell activation, and antiviral response. Approved in over 35 countries as Zadaxin® for hepatitis B.

Synthetic 29-amino acid GHRH analog, the first FDA-approved GH-releasing peptide (Geref®). Stimulates natural pulsatile GH secretion from the pituitary.

Mitochondria-targeted tetrapeptide researched for restoring cellular energy production, reducing oxidative stress, and treating mitochondrial dysfunction.

Small-molecule NNMT inhibitor researched for fat cell metabolism, NAD+ salvage pathway regulation, and metabolic health.

Neuropeptide encoded by the KISS1 gene, researched for reproductive hormone regulation, puberty onset, and fertility treatment.

Synthetic analog of the growth-hormone 176–191 lipolytic region — developed by Metabolic Pharmaceuticals and the version advanced into human trials. A distinct compound from HGH Fragment 176–191, not an alias.

Linear alpha-MSH analog (afamelanotide) approved in the EU as Scenesse® for erythropoietic protoporphyria. Researched for photoprotective tanning.

Modified insulin-like growth factor-1 with extended half-life (20+ hours). Researched for muscle growth, recovery, and cell proliferation.

Research peptide tracked on Peptigrity.

GHRH analog with a Drug Affinity Complex that extends half-life to 6-8 days, producing sustained GH elevation from a single weekly injection.

Synthetic 11-amino acid peptide derived from erythropoietin (EPO), researched for neuroprotection, tissue repair, and anti-inflammatory effects without erythropoiesis.

GH-secretagogue blend — CJC-1295 (no-DAC) and Ipamorelin, typically 5 mg each.

Four-peptide research blend — GHK-Cu, BPC-157, TB-500 and KPV in one vial.

Synthetic octapeptide researched for reducing wrinkle depth by modulating SNARE complex formation, mimicking a topical alternative to botulinum toxin.

Three-peptide research blend — GHK-Cu, BPC-157 and TB-500; formula varies by vendor.

Bioregulatory tripeptide targeting the pineal gland, researched for neuroprotection, cognitive preservation, and melatonin regulation.

28-amino-acid neuropeptide researched for immune regulation, neuroprotection, and circadian rhythm modulation.

The only human cathelicidin antimicrobial peptide with broad-spectrum activity against bacteria, viruses, and fungi.

Synthetic fragment of human growth hormone (amino acids 176-191), researched specifically for lipolysis and fat metabolism without GH's proliferative effects.

Research peptide tracked on Peptigrity.

Research peptide tracked on Peptigrity.

Research peptide tracked on Peptigrity.

Synthetic hexapeptide GH secretagogue that strongly stimulates growth hormone release and appetite via the ghrelin receptor.

Thymic polypeptide complex researched for immune reconstitution and anti-aging effects. Developed in Russia by Vladimir Khavinson.

Dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim, in Phase 3 trials for obesity and MASH (metabolic-associated steatohepatitis).

Synthetic hexapeptide growth hormone secretagogue that stimulates GH release via the ghrelin receptor. Stronger GH response than GHRP-6 but with moderate appetite effects.

Acetylated/amidated Semax analog (Ac-MEHFPGP-NH₂). Longer half-life than plain Semax. Distinct compound, not an alias.

Two-peptide tissue-repair blend — BPC-157 and TB-500 in a 1:1 ratio.

GH-secretagogue blend — Tesamorelin (the only FDA-approved ingredient across these blends) and Ipamorelin, typically 10:3.

Neuroprotective octapeptide from ADNP researched for microtubule stabilization and cognitive preservation.

Dual GLP-1/glucagon receptor agonist developed by Innovent Biologics, in clinical trials for obesity and metabolic liver disease.

Synthetic copper peptide researched for hair follicle stimulation, VEGF angiogenesis, and collagen production.

PEGylated mechano growth factor — a modified IGF-1 splice variant with extended half-life, researched for muscle repair and satellite cell activation.

Synthetic hexapeptide GH secretagogue with the strongest growth hormone release of any GHRP. Also researched for cardiac tissue protection.

Research peptide tracked on Peptigrity.

Research peptide tracked on Peptigrity.

Research peptide tracked on Peptigrity.

Research peptide tracked on Peptigrity.

AMPK activator (aminoimidazole carboxamide ribonucleotide) researched as an exercise mimetic for endurance, fat oxidation, and metabolic regulation.

Anticancer research peptide that selectively targets membrane-associated HDM-2 on tumor cells, inducing membranolysis without affecting normal cells.

Research peptide tracked on Peptigrity.

Research peptide tracked on Peptigrity.

A seven-amino-acid analog of the natural peptide spadin — a highly selective and potent blocker of the TREK-1 potassium channel, studied in animal models for fast-onset antidepressant-like effects and enhanced hippocampal neurogenesis.

Research peptide tracked on Peptigrity.

Research peptide tracked on Peptigrity.

Activin-binding glycoprotein that inhibits myostatin, researched for promoting muscle growth, reducing fibrosis, and supporting tissue remodeling.

Research peptide tracked on Peptigrity.

Research peptide tracked on Peptigrity.

Investigational small-molecule pan-ERR agonist (ERRα/β/γ) developed in the Burris laboratory, studied in animal models as an "exercise mimetic" for mitochondrial function, fat oxidation, and endurance capacity.

A neurotrophic peptide preparation from porcine brain — a mixture of low-molecular-weight peptides and free amino acids mimicking the body's own neurotrophic factors, used for stroke, TBI, and dementia in many countries (though not FDA-approved).

Peptidomimetic that targets PROHIBITIN on the vasculature of white adipose tissue, causing apoptosis of fat-supplying blood vessels and fat cell death.

Novo Nordisk's fixed-dose combination of the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide — a once-weekly obesity injection that pairs two complementary appetite pathways, currently under FDA review.

A synthetic Khavinson tetrapeptide (Ala-Glu-Asp-Pro) derived from the brain-cortex extract cortexin, researched as a central-nervous-system bioregulator for neuroprotection and cognitive-aging models.

Investigational small-molecule triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed by NeuroSearch, researched for appetite suppression and weight management.

A zinc-dependent thymic nonapeptide hormone (formerly "FTS") produced by thymic epithelial cells, researched for T-cell differentiation, immune modulation, and age-related immune decline.

Truncated IGF-1 variant missing the first 3 amino acids, resulting in reduced IGFBP binding and enhanced local anabolic potency.

The 344-amino-acid precursor isoform of follistatin — a high-affinity myostatin and activin neutralizer researched to release the body's brake on muscle growth, and the isoform most used in injectable and gene-therapy research.

A soluble activin receptor type IIB–Fc fusion protein (a myostatin and activin "ligand trap") developed by Acceleron Pharma to build muscle in muscular dystrophy — whose clinical development was discontinued after vascular safety events.

A topical cosmetic hexapeptide often called "topical Botox" — it mimics the SNAP-25 protein to interfere with SNARE-complex assembly, modestly reducing the muscle contractions behind dynamic expression lines.

A widely discussed tissue-repair research stack combining BPC-157 (gastric repair peptide), TB-500 (actin-regulating repair peptide), and KPV (an anti-inflammatory tripeptide) — three complementary angles on healing and inflammation.

A GH secretagogue stack pairing the GHRH analog CJC-1295 with GHRP-6, the ghrelin-mimetic best known for strongly stimulating appetite.

An angiotensin IV-derived peptidomimetic engineered for blood-brain-barrier penetration and oral activity, researched for its ability to potentiate hepatocyte growth factor (HGF)/c-Met signaling and drive hippocampal synapse formation.

Glycoprotein hormone that stimulates red blood cell production (erythropoiesis). FDA-approved for anemia treatment. Known for endurance performance effects.

A stack pairing the lipolytic HGH Fragment 176-191 with a clean GH secretagogue base — the GHRH analog CJC-1295 plus the selective Ipamorelin.

A 24-amino-acid mitochondrial-derived peptide — the first of its class to be discovered — researched for anti-apoptotic cytoprotection, neuroprotection, and insulin sensitivity.

The first non-peptide oral small-molecule GLP-1 receptor agonist approved for chronic weight management — a once-daily pill from Eli Lilly (discovered by Chugai), FDA-approved 1 April 2026 as Foundayo™.

A "clean" GH secretagogue stack pairing the GHRH(1-29) analog Sermorelin with Ipamorelin — the most selective GHRP, with minimal cortisol, prolactin, or appetite effects.

A triple GH stack combining two GHRH analogs — Tesamorelin (a stabilized GHRH, FDA-approved standalone for HIV-associated lipodystrophy) and CJC-1295 — with the selective GHRP Ipamorelin.

The full 43-amino-acid endogenous peptide and the body's principal actin-sequestering molecule — the parent compound behind most tissue-repair, wound-healing, and cardiac research, and the full-length counterpart to the shorter TB-500 fragment.

Novo Nordisk's investigational, first-in-class unimolecular GLP-1 and amylin receptor co-agonist, in development in both oral and subcutaneous forms and in Phase 3 since Q1 2026.

A two-part research stack pairing BPC-157 (gastric repair peptide) with KPV (an anti-inflammatory α-MSH tripeptide) — often discussed together for gut and tissue inflammation.

A cognitive research stack pairing Selank (an anxiolytic regulatory peptide) with Semax (a nootropic, neuroprotective peptide) — two Russian-developed peptides combined to pair calm with focus.

A growth-hormone secretagogue stack pairing the GHRH analog CJC-1295 with the potent ghrelin-mimetic GHRP-2 — two receptors, one amplified GH pulse.

A GH secretagogue stack pairing the GHRH analog CJC-1295 with Hexarelin — the most potent of the GHRPs, though the quickest to desensitize.

A triple growth-hormone stack combining the GHRH analog CJC-1295 with two ghrelin-mimetics — the selective Ipamorelin and the potent GHRP-2.

Pfizer's oral small-molecule (non-peptide) GLP-1 receptor agonist — a once-promising obesity candidate whose development was discontinued after a hepatotoxicity signal.

A once-weekly GLP-1 receptor agonist built as an Fc-fusion protein, FDA-approved as Trulicity® for type 2 diabetes and cardiovascular risk reduction.

A once-weekly, cAMP-biased GLP-1 receptor agonist developed by Sciwind Biosciences — the world's first approved biased GLP-1RA, cleared in China for type 2 diabetes and weight management (not FDA/EMA-approved).

A 39-amino-acid GLP-1 receptor agonist and synthetic form of exendin-4 (originally from Gila monster venom) — the first-in-class incretin mimetic, FDA-approved as Byetta® and Bydureon®.

A 15-amino-acid peptide derived from the FG loop of the neural cell adhesion molecule (NCAM) — a mimetic that activates the fibroblast growth factor receptor (FGFR1) to promote synapse formation, neurogenesis, and memory in preclinical models.

Growth differentiation factor 11 — a TGF-β-superfamily protein and close homologue of myostatin, studied as a circulating "rejuvenation factor" for heart, brain, and muscle aging, though its anti-aging role remains scientifically contested.

A once-daily GLP-1 receptor agonist, FDA-approved as Victoza® for type 2 diabetes and Saxenda® for chronic weight management — one of the most established incretin therapies.

A collagen-signaling "matrikine" peptide — a fragment of collagen linked to a fatty-acid chain for skin penetration — and the best-studied topical anti-aging peptide, with independent clinical data behind its wrinkle-softening claim.

Sederma's second-generation anti-aging peptide blend — pairing a collagen-signaling peptide (palmitoyl tripeptide-1) with an anti-inflammatory one (palmitoyl tetrapeptide-7) to address both collagen synthesis and its inflammatory breakdown.

A splice variant of IGF-1 (IGF-1Ec) whose unique C-terminal E-peptide is produced locally in mechanically stressed or damaged muscle, where it activates satellite (muscle stem) cells as an early trigger of repair.

A metabolic and longevity-oriented stack combining 5-Amino-1MQ, MOTS-c, and NAD⁺ — three compounds aimed at cellular energy metabolism from different angles.

Orally active, non-peptide ghrelin-receptor (GHSR-1a) agonist and growth hormone secretagogue developed by Merck, researched for sustained GH and IGF-1 elevation, body composition, bone density, and sleep.

A synthetic nootropic dipeptide (INN omberacetam) developed in Russia — a prodrug of the endogenous neuropeptide cycloprolylglycine that enhances cognition and neuroprotection at doses roughly 1,000× lower than piracetam.

An anti-inflammatory cosmetic peptide (trade name Rigin) derived from an antibody fragment — it suppresses the cytokine interleukin-6 to reduce the inflammation-driven collagen breakdown of "inflammaging", and is one of the two peptides in Matrixyl 3000.

A palmitoylated form of the GHK tripeptide — a collagen-signaling matrikine that tells fibroblasts to build collagen and fibronectin, and one of the two peptides in the Matrixyl 3000 blend.

Altimmune's investigational, balanced 1:1 GLP-1/glucagon dual receptor agonist, in Phase 2 development for obesity and MASH — with FDA Breakthrough Therapy designation for MASH.

The arginine-salt form of BPC-157 — the same 15-amino-acid gastric pentadecapeptide (GEPPPGKPADDAGLV), marketed as a more stable salt variant and researched for tissue repair, tendon and gut healing, and angiogenesis.

Zealand Pharma and Roche's investigational long-acting amylin analog for chronic weight management, advancing toward Phase 3 on the strength of double-digit weight loss with placebo-like tolerability.

A synthetic analog of the pancreatic hormone amylin, FDA-approved as Symlin® as a mealtime adjunct to insulin — researched for glucose control, appetite suppression, and weight management.

A retinal polypeptide bioregulator — a complex of water-soluble polypeptide fractions isolated from cattle retina — used as a retinoprotector in Russia for retinal and optic-nerve disorders, though it is not approved by the FDA or EMA.

A GH secretagogue stack pairing the GHRH(1-29) analog Sermorelin with the potent ghrelin-mimetic GHRP-2 — a classic amplitude-plus-frequency combination.

A GH secretagogue stack pairing the GHRH(1-29) analog Sermorelin with GHRP-6, the ghrelin-mimetic best known for stimulating appetite.

A triple GH stack pairing the GHRH analog Sermorelin with two ghrelin-mimetics — GHRP-6 (appetite-driving) and GHRP-2 (potent).

Viking Therapeutics' investigational dual GLP-1/GIP receptor agonist, in development in both oral and subcutaneous forms and in Phase 3 trials for obesity.